American Society of Hirudotherapy

The history of leeching and hirudin

Historical review published in Haemostasis (1991)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Drug DevelopmentSalivary PharmacologyGenomics & ProteomicsFields W · Haemostasis, 1991

Abstract

Leeching is an art dating back at least to ancient Egypt. It reached its zenith in the late 18th and early 19th centuries. The antithrombotic quality of leech saliva was first noted by Haycraft in 1884 and the active anticoagulant ingredient isolated in 1904 by Jacoby. He gave this agent the name 'hirudin'. Hirudin was isolated in pure crystalline form by Markwardt in 1957 and first produced in quantity by genetic engineering in 1986. The salivary glands of several species of leech also contain other biologically active substances which are currently undergoing investigation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeHistorical ArticleJournal Article
Indexed MeSH termsAnimalsBloodlettingHirudin TherapyHirudinsHistory, 15th CenturyHistory, 16th CenturyHistory, 17th CenturyHistory, 18th CenturyHistory, 19th CenturyHistory, 20th CenturyHistory, AncientHistory, MedievalHumansLeechesRecombinant Proteins

Summary

This account traces leeching from ancient Egypt through its 18th–19th-century peak and reviews the recognition of leech saliva's anticoagulant (Haycraft 1884), isolation of hirudin (Jacoby 1904), its crystallization (Markwardt 1957) and 1986 recombinant production; other salivary factors remain under study.

Why This Matters for Hirudotherapy

This historical article traces the practice of leeching from ancient Egypt through its peak in the late 18th and early 19th centuries and chronicles the scientific characterization of hirudin — from Haycraft's 1884 observation of leech saliva's antithrombotic properties, to Jacoby's 1904 isolation and naming of the active anticoagulant, to Markwardt's 1957 crystallization, and finally to genetically engineered production in 1986. It provides foundational context showing how hirudotherapy and the leech salivary secretome evolved from empirical practice to defined pharmacology, while noting that several biologically active substances beyond hirudin in leech saliva were, at the time of writing, under active investigation. As a historical article, it contains no original experimental data, no clinical outcomes, and no new primary findings; it is a retrospective narrative of previously established milestones and therefore offers background perspective rather than evidence for contemporary practice.

Citation

Reference (Vancouver style)

Fields WS. The history of leeching and hirudin. Haemostasis. 1991;21 Suppl 1:3-10. doi:10.1159/000216256. PMID: 1894194

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: March 18, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.